MAP2K1 and cancer: Using MEFs and cancer cell lines, we performed co-treatment with 249C and the following MAPK pathway inhibitors: AMG510 (KRASG12C); Dabrafenib (BRAFV600); Trametinib (MEK1/2); and SCH772984 (ERK1/2) (Supplementary Fig. 9a).